General POCT & Technology
Our POCT solutions are designed for rapid decision-making. For instance, the Poclight CLIA system delivers results in as little as 3 minutes, while the Genedrive molecular system provides qualitative results for critical genetic tests like MT-RNR1 in approximately 26 minutes. This eliminates the days of waiting associated with central lab transport and batch processing.
No, many of our key products utilise lyophilised (freeze-dried) bead technology. For example, the Genedrive CYP2C19 ID Kit is shipped and stored at room temperature. Similarly, the Poclight system uses “lyophilized beads,” ensuring no cold chain is required, which significantly reduces logistics costs and storage complexity.
Yes, connectivity is a standard feature. The Poclight C5000 supports LIS connectivity for efficient sample management. Likewise, the Genedrive system can upload results via Wi-Fi or Ethernet to a secure server, facilitating integration with electronic patient records.
Clinical Applications
The kit identifies CYP2C19 genetic variants (*2, *3, *4, *8, *17, *35) that affect how patients metabolise Clopidogrel. By delivering results quickly (point-of-care), clinicians can identify patients who are Poor or Intermediate Metabolisers and prescribe alternative antiplatelet therapies (like Ticagrelor or Prasugrel) immediately, reducing the risk of recurrent stroke.
This test detects the m.1555A>G mutation in the MT-RNR1 gene. Identifying this variant in newborns before administering aminoglycoside antibiotics (often used for sepsis) can prevent antibiotic-induced hearing loss (ototoxicity). The test is non-invasive (buccal swab) and rapid enough to be used in a neonatal intensive care setting
The Poclight C5000 offers a comprehensive menu covering Inflammation (CRP, SAA, PCT, IL-6), Cardiac Markers (hs-cTnI, NT-proBNP, Myo), Hormones (TT3, TT4, TSH), Tumor Markers (AFP, CEA), Diabetes (HbA1c), and more. It is a 7-channel system capable of running multiple parameters
Operations & Cost
No. The Poclight C5000 features a “maintenance-free” design, requiring no maintenance for up to 600 days. It uses single-use cartridges and a liquid-free system, eliminating the need to clean internal structures daily.
While unit costs may vary, POCT can generate significant system-wide savings. For example, a model in NHS Scotland showed that using the Genedrive CYP2C19 test could save £18 million over 5 years by preventing recurrent strokes compared to standard care. Similarly, avoiding hearing loss with the MT-RNR1 test saves lifetime costs associated with deafness
No, the systems are designed for ease of use. The Genedrive system, for example, automates the analysis and interpretation, providing a clear result without requiring complex data analysis. It also includes features like reagent lock-outs to prevent errors. Nurses and non-lab staff can operate it effectively after simple training